Recent outstanding clinical results produced by engineered T cells, including chimeric antigen receptors, have already facilitated further research that broadens their applicability. One such direction is to explore new T cell sources for allogeneic "offthe-shelf" adoptive immunotherapy. Human pluripotent stem cells could serve as an alternative cell source for this purpose due to their unique features of infinite propagation ability and pluripotency. Here, we describe the current state of engineered T cell transfer with the focus on cell manufacturing processes and the potentials and challenges of induced pluripotent stem cell-derived T cells as a starting material to construct off-the-shelf T-cell banks.
| INTRODUC TI ON
Cancer immunotherapy has become an emerging entity for cancer 
| ENG INEERED T CELL S FOR C AN CER THER APY
Adoptive T cell transfer for cancer immunotherapy was initially demonstrated by the Rosenberg Laboratory in the NCI, USA, using T cells isolated from a patient's tumor on surgery, also known as tumor-infiltrating lymphocytes (TILs). The isolated TILs are subsequently expanded ex vivo to obtain clinically relevant numbers for reinfusion. 2 Since then, alternative approaches have been proposed and evaluated. Among them, Carl June's group at the University of Pennsylvania, USA, showed the feasibility of adoptive transfer of bulk T cells from peripheral blood (PBT) of patients expanded ex vivo in the presence of interleukin (IL)-2. 3 The first clinical trial using the expanded PBT was implemented on patients with relapsed/refractory non-Hodgkin lymphoma following hematopoietic stem cell transfer and showed the safety of the procedure. 4 These two seminal studies used a population of T cells with unknown antigen-specificity.
Researchers have also explored the potentials of tumor-antigen directed engineered T cells obtained from patient's blood. 5, 6 The manufacturing process involves isolation of PBT from patients and ex vivo expansion followed by retroviral transduction of a T-cell receptor (TCR) or CAR. For example, CAR T cells are generated from bulk PBMCs by aphaeresis, activated with CD3/28 beads, and transduced with a viral vector harboring CAR. These production processes take approximately 10-14 days to obtain cell doses required for reinfusion. Importantly, the potential of engineered T cells has been well demonstrated in clinical trials obtained with NY-ESO-1 TCR 7 and CD19 CAR. [8] [9] [10] [11] Last year, Novartis announced that the US FDA approved Kymriah (tisagenlecleucel), the first CAR-T therapy product, for B-cell precursor acute lymphoblastic leukemia. The price tag of Kymriah was determined to be $475 000 per patient, which astonished the community. Although the therapeutic benefits of engineered T cells are now apparent, several issues remain to be solved. 19 Clearly, cost of the products needs to be reduced in order to make it economically practical. One approach under evaluation is allogeneic therapy. Autologous T cell therapy will remain in the frontline of target validation and the production cost will be reduced with upcoming new technologies. Once the efficacy of a target is validated, then the development of banked T-cell source that is immediately ready upon the need would contribute to broaden the applicability and cost reduction of adoptive T cell therapies. 
| PLURIP OTENT S TEM CELL S A S TRUE "OFF-THE-S HELF" T CELL S IN THE ER A OF SYNTHE TI C B I OLOGY
Since reported in 1998, human ESCs have been expected to become an ultimate cell source for regenerative medicine due to the features of pluripotency; they can be propagated indefinitely while maintaining the ability to differentiate into all types of somatic cells in vitro. The proliferative ability of redifferentiated T cells was remarkably higher than those of the original T cell clone. This technique allows us to generate a large number of rejuvenated T cell clones. In addition, the feasibility of generation of CAR-T cells from iPSCs has been reported. 30 Collectively, these studies showed the proof-of-concept that T cells with antigen-specific activities could be generated from pluripotent stem cells by TCRs and CARs.
Although the aforementioned studies show the potential of iPSCderived T cells as an alternative cell source for T cell immunotherapy, recent studies, including those at our laboratory, revealed that T cells differentiated from iPSCs using the current differentiation methods display features similar to γδT cells or innate lymphoid cells. 
Generation of T cells from PSCs requires comprehensive under-
standing of developmental biology and immunology to recapitulate the key events that occur during T cell commitment. 33 The key events are illustrated in Figure 4 . The initial event is the induction of mesoderm, which is followed by hemogenic endothelial cell derivation.
The next key step is called endothelial-to-hematopoietic transition, the mechanism through which heterogeneous populations of HSPCs are generated. 34 The other milestone is to induce T cell commitment cesses and deal with regulatory requirements must not be overlooked.
Although we described the properties of iPSC T cells, other considerations need to be made when undertaking allogeneic therapy.
One of them is to circumvent the risk of rejection, given that longterm persistence correlates to therapeutic efficacy by CD19-CART therapy. Accumulating evidence from allogeneic renal and bone marrow transplantations suggests that matching HLA-A, -B, and -DR are beneficial to graft survival, indicating that HLA matching would be preferred in allogeneic iPSC-T cell therapy. [38] [39] [40] [41] [42] Accordingly, banking of iPSCs generated from common HLA-homozygous donors has been proposed and is currently under development at the Center for iPS
Research and Application (CiRA), Kyoto University. 43 In CiRA, it has been estimated that an iPSC bank with 50 unique HLA-homozygous iPSC lines would cover approximately 73% of the Japanese population, assuming matching at HLA-A, -B, and -DRB1 loci. 44 Similarly, another study also estimated generating 150 selected HLA homozygous lines would match 93% of the UK population. 45 To date, CiRA has already accomplished the development and delivery of the first HLA-homozygous iPSC, which will match to approximately 17% of the Japanese population and several clinical studies are underway or under planning using the iPSC grafts. For allogeneic iPSC-T cell therapy, HLA-homozygous iPSCs transduced with either CAR or TCR will be used as a starting material to construct an iPSC-T cell bank. Other strategy actively considered is generation of "the universal donor" iPSC by disrupting HLA genes. In addition to HLA deletion, a recent report showed that overexpression of HLA-E in HLA-deficient iPSCs reduced natural killer cell-mediated rejection, which is augmented when HLA genes are disrupted. 46 The other critical issue that is worth mentioning is how we manage the risk of alloreactivity of infusing T cells. Alloreactivity would be a particular concern to allogeneic T cell therapy as it may attack and destroy host tissues. Therefore, the choice of TCRs will be critical to overall therapeutic benefits to patients. One approach to this problem would be to use Epstein-Barr virus-reactive TCRs.
Alternatively, deletion of TCRs by the means of genome editing could minimize the alloreactivity, as reported by a recent study. 47 Finally, once clinical potentials are evaluated, iPSC-derived T cell technology could become the best platform to undertake gene manipulations to enhance functions or even add desired functions.
For example, a recent study showed a proof of concept that overexpression of IL-7 and CCL19 in CAR, designated as 7 × 19 CAR-T cells, significantly enhanced in vivo antitumor functions. 48 
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